Spinogenix's SPG601 Receives FDA Fast Track Designation for Fragile X Syndrome

Published Date: 19 Jan 2025

The company announced the completion of its phase 2 study assessing SPG601 in adult men with FXS, with topline findings expected to be reported by end of the first quarter in 2025.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

2.

Detecting pancreatic cancer through changes in body composition and metabolism

3.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.

4.

The pandemic had little impact on mental health symptoms.

5.

Men over 75 years old may be significantly more likely to commit suicide if they have cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot